This site is intended for healthcare professionals

Older woman with Alzheimers staring out of a window, confused

Alzheimer's Disease

Last updated: 26th Jul 2024

Alzheimer's Disease is a neurodegenerative disease where the build-up of the proteins amyloid and tau damage the nerve cells in the brain. A progressive disorder, Alzheimer’s develops over time with symptoms increasing in severity.

Between 60–80% of dementia cases are caused by Alzheimer's disease. Rapid diagnosis is important, as treatment early in the course of AD helps maintain cognitive and functional performance and delay the emergence of distressing behavioural and psychological symptoms, such as depression, anxiety and apathy.

Cholinesterase inhibitors can be used alone or in combination to manage the behavioural and psychological symptoms of Alzheimer's disease. However current treatments do not cure Alzheimer's disease and functional and cognitive decline are inevitable.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Related news and insights

Ozempic (semaglutide) cuts dementia risk compared with Januvia (sitagliptin): Oxford study.-Novo Nordisk

Trials have already shown that Novo Nordisk’s semaglutide can cut the risk of cardiovascular events and kidney disease. Now a study from the University of Oxford indicates that the company’s semaglutide type 2 diabetes drug Ozempic can reduce the risk of dementia compared with another popular diabetes medicine.

1 mins

Cassava Sciences issues statement on former science advisor.

Cassava Sciences, Inc. reported it has learned that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university’s medical school as well as a former paid science advisor to Cassava Sciences

1 min

Kisunla (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer's disease

The FDA approved Kisunla (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology

2 min

See all news

Related Journal Articles

Neuropathology of Alzheimer's disease.

1 mins

A vaccine against Alzheimer`s disease: anything left but faith?

1 mins

Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies.

1 mins

Impaired brain plasticity as a potential therapeutic target for treatment and prevention of dementia.

1 mins

Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease.

1 mins

Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.

1 mins

Effects of dementia knowledge and dementia fear on comfort with people having dementia: Implications for dementia-friendly communities.

1 mins

Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier.

1 mins

Personality Change in the Preclinical Phase of Alzheimer Disease.

1 mins

Review: Clinical, neuropathological and genetic features of Lewy body dementias.

1 mins

Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review.

1 mins

Diffusion tensor imaging of white matter degeneration in early stage of Alzheimer's disease: a review.

1 mins

Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview.

1 mins

Role of monocarboxylate transporter 4 in Alzheimer disease.

1 mins

A systematic review of the integration of palliative care in dementia management.

1 mins

Heterogeneity of Alzheimer's disease: consequence for drug trials?

1 mins

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

1 mins

Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia.

1 mins

Gray Matter Changes Associated With the Development of Delusions in Alzheimer Disease.

1 mins

Characterising omission errors in everyday task completion and cognitive correlates in individuals with mild cognitive impairment and dementia.

1 mins

Alzheimer's disease pathogenesis: The role of disturbed sleep in attenuated brain plasticity and neurodegenerative processes.

1 mins

A randomized, single ascending dose study of intravenous BIIB092 in healthy participants.

1 mins

Cognitive intervention for early stage dementia: Research and techniques.

1 mins

Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

1 mins

Aggressive Behaviors in Alzheimer Disease and Mild Cognitive Impairment: Systematic Review and Meta-Analysis.

1 mins

The promise of technology in the future of dementia care.

1 mins

A pilot study of exenatide actions in Alzheimer's disease.

1 mins

Relationship between long non-coding RNAs and Alzheimer's disease: a systematic review.

1 mins

Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.

1 mins

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

1 mins

Related Guidelines

Dementia: assessment, management and support for people living with dementia and their carers

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease).

1 mins

Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the BAP

The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs.

1 min

See all guidelines

Related Clinical Trials

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

1 mins

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (ENVISION)

1 mins

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

1 mins

A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease

1 mins

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

1 mins

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

1 mins

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

1 mins

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

1 mins

Tricaprilin Phase 3 AD Study

1 mins